Loading...
Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
Abou-Alfa, GK Borbath, I Clarke, SJ Hitre, E Louvet, C Macarulla, T Oh, DY Spratlin, JL Valle, Juan W Weiss, KH
Abou-Alfa, GK
Borbath, I
Clarke, SJ
Hitre, E
Louvet, C
Macarulla, T
Oh, DY
Spratlin, JL
Valle, Juan W
Weiss, KH
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Abou-Alfa GK, Borbath I, Clarke SJ, Hitre E, Louvet C, Macarulla T, et al. 832TiP Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. Annals of Oncology. 2019;30(Supplement_5).